Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUNDTRACK-B: surovatamig monotherapy in relapsed/refractory follicular lymphoma or large B-cell lymphoma
jRCT2071240051Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of surovatamig in mature B-cell lymphoma, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AstraZeneca. Primary endpoint: Overall response rate. Started Jan 2025; status: recruiting.
02
Drugs
surovatamig
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2071240051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240051.